In addition, CDK1 inhibitors could eliminate the effect of YOD1 overexpression (the proliferation and resistance to cisplatin), which further elucidates the tumor promoting mechanism of the YOD1-CDK1 axis. The gene discussed is CDK1; the disease is neoplasm.